Last reviewed · How we verify

ADT (Standard of Care)

Aragon Pharmaceuticals, Inc. · Phase 3 active Small molecule

ADT (Standard of Care) is a Hormonal therapy / Androgen deprivation Small molecule drug developed by Aragon Pharmaceuticals, Inc.. It is currently in Phase 3 development for Metastatic hormone-sensitive prostate cancer, Locally advanced prostate cancer (in combination with radiation therapy), Biochemically recurrent prostate cancer. Also known as: LHRH agonists, LHRH antagonists.

ADT (Androgen Deprivation Therapy) suppresses testosterone production or blocks androgen receptor signaling to inhibit growth of androgen-dependent prostate cancer cells.

ADT (Androgen Deprivation Therapy) suppresses testosterone production or blocks androgen receptor signaling to inhibit growth of androgen-dependent prostate cancer cells. Used for Metastatic hormone-sensitive prostate cancer, Locally advanced prostate cancer (in combination with radiation therapy), Biochemically recurrent prostate cancer.

At a glance

Generic nameADT (Standard of Care)
Also known asLHRH agonists, LHRH antagonists
SponsorAragon Pharmaceuticals, Inc.
Drug classHormonal therapy / Androgen deprivation
TargetAndrogen receptor / GnRH receptor (depending on specific ADT agent)
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

ADT is a standard-of-care hormonal therapy approach for prostate cancer that works by either reducing circulating testosterone levels (via GnRH agonists/antagonists or surgical castration) or blocking androgen receptor function (via antiandrogens). This starves androgen-dependent prostate cancer cells of the hormonal signals required for proliferation and survival.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about ADT (Standard of Care)

What is ADT (Standard of Care)?

ADT (Standard of Care) is a Hormonal therapy / Androgen deprivation drug developed by Aragon Pharmaceuticals, Inc., indicated for Metastatic hormone-sensitive prostate cancer, Locally advanced prostate cancer (in combination with radiation therapy), Biochemically recurrent prostate cancer.

How does ADT (Standard of Care) work?

ADT (Androgen Deprivation Therapy) suppresses testosterone production or blocks androgen receptor signaling to inhibit growth of androgen-dependent prostate cancer cells.

What is ADT (Standard of Care) used for?

ADT (Standard of Care) is indicated for Metastatic hormone-sensitive prostate cancer, Locally advanced prostate cancer (in combination with radiation therapy), Biochemically recurrent prostate cancer.

Who makes ADT (Standard of Care)?

ADT (Standard of Care) is developed by Aragon Pharmaceuticals, Inc. (see full Aragon Pharmaceuticals, Inc. pipeline at /company/aragon-pharmaceuticals-inc).

Is ADT (Standard of Care) also known as anything else?

ADT (Standard of Care) is also known as LHRH agonists, LHRH antagonists.

What drug class is ADT (Standard of Care) in?

ADT (Standard of Care) belongs to the Hormonal therapy / Androgen deprivation class. See all Hormonal therapy / Androgen deprivation drugs at /class/hormonal-therapy-androgen-deprivation.

What development phase is ADT (Standard of Care) in?

ADT (Standard of Care) is in Phase 3.

What are the side effects of ADT (Standard of Care)?

Common side effects of ADT (Standard of Care) include Hot flashes, Erectile dysfunction, Decreased libido, Gynecomastia, Fatigue, Bone loss / osteoporosis.

What does ADT (Standard of Care) target?

ADT (Standard of Care) targets Androgen receptor / GnRH receptor (depending on specific ADT agent) and is a Hormonal therapy / Androgen deprivation.

Related